カレントテラピー　31-2サンプル page 26/34

このページは カレントテラピー　31-2サンプル の電子ブックに掲載されている26ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
治療薬解説14）Calhoun DA, White WB：Effectiveness of the selective aldosteroneblocker, eplerenone, in patients with resistant hypertension.J Am Soc Hypertens 2：462-468, 200815）Mann SJ：Combinedα/β....

治療薬解説14）Calhoun DA, White WB：Effectiveness of the selective aldosteroneblocker, eplerenone, in patients with resistant hypertension.J Am Soc Hypertens 2：462-468, 200815）Mann SJ：Combinedα/β- Blockade：an underusedapproach to the treatment of resistant hypertension. J ClinHypertens（Greenwich）9：663 -666, 200716）Mann SJ, Parikh NS：A simplified mechanistic algorithm fortreating resistant hypertension：efficacy in a retrospectivestudy. J Clin Hypertens（Greenwich）14：191-197, 201217）Hermida RC, Ayala DE, Fernandez JR, et al：Chronotherapyimproves blood pressure control and reverts the nondipperpattern in patients with resistant hypertension. Hypertension51：69 -76, 200818）Hermida RC, Ayala DE, Mojon A, et al：Influence of circadiantime of hypertension treatment on cardiovascular risk：results of the MAPEC study. Chronobiol Int 27：1629 -1651,201019）Oliveria SA, Lapuerta P, McCarthy BD, et al：Physician -related barriers to the effective management of uncontrolledhypertension. Arch Intern Med 162：413-420, 200220）Persson M, Carlberg B, Tavelin B, et al：Doctors’estimationof cardiovascular risk and willingness to give drug treatmentin hypertension：fair risk assessment but defensive treatmentpolicy. J Hypertens 22：65 -71, 200421）Yusuf S, Teo KK, Pogue J, et al；ONTARGET Investigators：Telmisartan, ramipril, or both in patients at high risk for vascularevents. N Engl J Med 358：1547-1559, 200822）Bobrie G, Frank M, Azizi M, et al：Sequential nephron blockadeversus sequential renin?angiotensin system blockade inresistant hypertension：a prospective, randomized, openblinded endpoint study. J Hypertens 30：1656-1664, 201223）桑島巌：J -CLEAR通信17利尿薬に違いあり―そのエビデンスを識る.日本医事新報4577：84 -87, 20122 4）E p s t e i n M , C a l h o u n D A：A l d o s t e r o n e B l o c k e r s（Mineralocorticoid Receptor Antagonism）and Potassium -Sparing Diuretics. J Clin Hypertens（Greenwich）13：644 -648, 201125）Khosla N, Kalaitzidis R, Bakris GL：Predictors of hyperkalemiarisk following hypertension control with aldosteroneblockade. Am J Nephrol 30：418-424, 200926）Krum H, Schlaich M, Whitbourn R, et al：Catheter -basedrenal sympathetic denervation for resistant hypertension：amulticentre safety and proof -of -principle cohort study.Lancet 373：1275-1281, 200927）Scheffers IJ, Kroon AA, Schmidli J, et al：Novel baroreflexactivation therapy in resistant hypertension：results of aEuropean multi -center feasibility study. J Am Coll Cardiol56：1254-1258, 201028）ALLHAT Officers and Coordinators for the ALLHATCollaborative Research Group. The Antihypertensive andLipid-Lowering Treatment to Prevent Heart Attack Trial：Major outcomes in high -risk hypertensive patients randomizedto angiotensin -converting enzyme inhibitor or calciumchannel blocker vs diuretic：the Antihypertensive andLipid -Lowering Treatment to Prevent Heart Attack Trial（ALLHAT）. JAMA 288：2981-2997, 200229）Ohta Y, Tsuchihashi T, Onaka U, et al：Usefulness of theα1 -blocker doxazosin as a third -line antihypertensive drug.Hypertens Res 30：301 -306, 200730）Searle M, Dathan R, Dean S, et al：Doxazosin in combinationwith atenolol in essential hypertension：a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol 39：299-300, 1990Current Therapy 2013 Vol.31 No.220997